Inactivation of NF-κB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells
- 6 December 2007
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 112 (1), 53-62
- https://doi.org/10.1007/s10549-007-9837-8
Abstract
Histone deacetylase inhibitors (HDACi) are a new class of anticancer agents that cause growth arrest, differentiation and/or apoptosis in many tumor cells. As acetylation regulates the activity of the anti-apoptotic transcription factor NF-kappaB, we investigated whether the proteasome inhibitor MG-132 would inhibit NF-kappaB activation and as a consequence potentiate HDACi-dependent apoptosis in breast cancer cells. We observed that the HDACi suberoylanilide hydroxamic acid (SAHA) or trichostatin A (TSA) induced cell death but also enhanced NF-kappaB-activity. This increase of NF-kappaB activity was strongly reduced by the addition of MG-132. Moreover, MG-132 potentiates the HDACi-induced cell death that was associated with caspase-3 activation, and PARP cleavage. Induction of the stress related kinases JNK and p38 and the up-regulation of p21 and p27 were also observed after co-treatment of cells with HDACi and MG-132. Disruption of the NF-kappaB pathway by BAY 11-7085 or IkappaB-SR mimicked the action of MG-132 in promoting HDACi-induced cell death. Thus, the combined treatment with HDACi and proteasome inhibitors potentiates apoptosis in breast cancer cells representing a novel strategy for breast cancer therapy.Keywords
This publication has 30 references indexed in Scilit:
- Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor ActivityClinical Cancer Research, 2006
- Acetylation and deacetylation of non-histone proteinsGene, 2005
- Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancerNature Genetics, 2005
- Nuclear factor-κBCancer Cell, 2004
- Shaping the nuclear action of NF-κBNature Reviews Molecular Cell Biology, 2004
- The IKK NF-κB system: a treasure trove for drug developmentNature Reviews Drug Discovery, 2004
- Post-activation Turn-off of NF-κB-dependent Transcription Is Regulated by Acetylation of p65Journal of Biological Chemistry, 2003
- Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaBThe EMBO Journal, 2002
- Histone-deacetylase inhibitors: novel drugs for the treatment of cancerNature Reviews Drug Discovery, 2002
- Roles of histone acetyltransferases and deacetylases in gene regulationBioEssays, 1998